Improved FDA Forensics Uncover More Manufacturing Data Integrity Issues
This article was originally published in PharmAsia News
Executive Summary
The US FDA learned how to find hidden information during its investigation of Ranbaxy, with techniques including improved forensic examinations of computers, and mock inspections are being held at some Indian and Chinese sites ahead of FDA visits.
You may also be interested in...
House Demands More Info On FDA Overseas Operations
GAO to report on foreign office closures and risk-based inspection policy amid concerns that unequal playing field remains.
Ranbaxy’s $500 Million Settlement Includes Criminal Penalties
The generic drug maker’s Ranbaxy USA Inc. subsidiary pleads guilty to seven felony counts brought in connection with a longstanding government investigation into data integrity issues and manufacturing violations at two Indian sites, but while the settlement eliminates some worries for the firm, operations still face the weight of a FDA consent decree.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.